TCR T-cell Therapies: What if Magic Bullets Simply Aren't Good Enough?
On the heels of a recent post in which I discussed evolving dynamics and strategic implications underscoring different types of...
Joel Sandler's Passles
Donor-derived T-cells vs. iPSC- and Cord-derived NKs: Allo Not Created Equal
A common question I get from my cancer cell therapy clients at Cello Health BioConsulting is why, despite the lion share of clinical data...
Next Wave AntiCancer Therapies Part 1
“In 1890, the Russian playwright and physician Anton Chekov wrote a letter in which he alluded to a centuries-old observation that...
Anticancer Cellular Immunotherapies: Optimizing the Path from Bench to FDA Approval
A striking number of anticancer cellular immunotherapies, also commonly referred to as adoptive cellular therapies (ACT), are in various...
Proliferation of Novel Cell Type Platforms in the Oncology Competitive Landscape-Part II
Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry,...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net